EVOMMUNE
Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines for inflammatory diseases.
EVOMMUNE
Industry:
Biotechnology Life Science
Founded:
2020-01-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.evommune.com
Total Employee:
1+
Status:
Active
Total Funding:
95.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Google Universal Analytics Mobile Non Scaleable Content Nginx Microsoft Exchange Online
Current Employees Featured
Eugene A. Bauer Co-Founder & Chief Medical Officer @ Evommune
Co-Founder & Chief Medical Officer
2020-04-01
Greg Moss Chief Corporate Strategy and Legal Officer @ Evommune
Chief Corporate Strategy and Legal Officer
2022-06-01
Janice Drew SVP, Product Development @ Evommune
SVP, Product Development
2020-07-01
Hans Hofland Senior Vice President Research @ Evommune
Senior Vice President Research
2020-07-01
Luis Pena Founder, President & CEO @ Evommune
Founder, President & CEO
2020-04-01
Ben McGraw Director @ Evommune
Director
2020-10-01
Founder
Investors List
LSP BioVentures
LSP BioVentures investment in Series A - Evommune
Andera Partners
Andera Partners investment in Series A - Evommune
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series A - Evommune
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Seed Round - Evommune
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-27 | Evommune Announces Appointment of Greg Moss as Chief Corporate Strategy and Legal Officer |
Official Site Inspections
http://www.evommune.com Semrush global rank: 5.65 M Semrush visits lastest month: 1.49 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Evommune"
Evommune | Chronic Inflammatory Disease Therapies
Chronic inflammation is increasingly recognized as an uncontrolled “pandemic,” acting as a common factor in the current erosion of life expectancy. 1 Worldwide, 3 of 5 people die from some form of chronic inflammatory disease. 2 The team …See details»
Evommune - Crunchbase Company Profile & Funding
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. …See details»
Chronic Inflammatory Disease Drugs | Leadership - Evommune
Learn about the leadership team at Evommune, a clinical stage biopharma developing novel therapies to treat immune-mediated chronic inflammatory diseases. Evommune Announces …See details»
Evommune - LinkedIn
Evommune | 3,243 followers on LinkedIn. Inventing ways to treat inflammatory diseases, developing therapies that address symptoms and halt progressive disease. | Chronic inflammatory diseases are ...See details»
Evommune, Inc. Company Profile | Palo Alto, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Evommune, Inc. of Palo Alto, CA. Get the latest business insights from Dun & Bradstreet.See details»
Evommune - Funding, Financials, Valuation & Investors - Crunchbase
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms. ... Log In. Log In. Experience the new Crunchbase, powered by …See details»
Evommune - Contacts, Employees, Board Members, Advisors
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms. ... Experience the new Crunchbase, powered by AI . Experience …See details»
Evommune Overview | SignalHire Company Profile
Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines for inflammatory diseases. ... Organization Website: …See details»
Evommune - VentureRadar
Evommune is using the skin as the lens to uncover new approaches for accelerating the development of vital medicines across immunology and dermatology. Utilizing a novel …See details»
Evommune - EQT Group
Evommune is developing and discovering unique therapies that help patients with chronic inflammatory diseases.See details»
Evommune In-Licenses Three Development Programs Focused on …
Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory …See details»
Evommune, Inc. Raises $12.5M in Seed Funding to Accelerate the ...
Nov 18, 2020 Evommune is a private, R&D company and innovation engine in chronic inflammation. Evommune is taking a tissue-based approach to advance insights and …See details»
Evommune Closes $50 Million Series B Financing to Advance …
Apr 26, 2023 Evommune was founded in 2020 by an industry-leading team of R&D experts and biotech company builders, and is headquartered in Palo Alto, California. For more information, …See details»
How Evommune is Redefining Treatments for Chronic …
Evommune’s disciplined approach and commitment to innovation position the company for continued success in the rapidly evolving field of immunology. With programs already in …See details»
Evommune Advances EVO756 Into Global Phase 2b Trial for …
5 days ago Evommune, Inc. announced today that it has officially launched its phase 2b clinical trial evaluating EVO756 for chronic spontaneous urticaria (CSU), marking the next step in the …See details»
Evommune | Chronic Inflammatory Disease Therapies | Pipeline
Check out the drug pipeline for Evommune, a clinical stage biopharma developing novel therapies to treat immune-mediated chronic inflammatory diseases. Evommune Announces Initiation of …See details»
Evommune gains funding to accelerate therapies for diseases
Apr 27, 2023 Evommune has received $50m in Series B financing to accelerate the development of therapies for the treatment of chronic inflammatory diseases. Co-led by new …See details»
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, …
5 days ago Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment …See details»
Evommune’s human tissue-based approach enables discovery and ...
Oct 11, 2022 Evommune’s senior leadership and scientific teams are primed to do just that. Throughout their careers, they have helped bring more than 25 medicines to patients in need. …See details»
Evommune Announces $115 Million Series C Financing to …
Oct 22, 2024 Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases. The company is …See details»